About Epigral Limited

Epigral Limited (formerly Meghmani Finechem Limited) was established in 2007 as a subsidiary of Meghmani Organics Limited and became an independent publicly listed company on August 18, 2021. The Company rebranded itself as Epigral Limited in 2023 to reflect its ambition of becoming a global, multi-product chemical conglomerate.

Its industrial journey began in 2009 with Chlor-Alkali operations, and over the years, it has expanded capacity across multiple product segments, including Caustic Soda, Epichlorohydrin (ECH), Chloromethanes, Hydrogen Peroxide, CPVC Resin, CPVC Compounds, and Chlorotoluenes. Today, Epigral operates a fully integrated, state-of-the-art manufacturing complex spanning 60 hectares in Dahej, Gujarat, supported by a captive 132 MW power plant and an 18.34 MW wind-solar hybrid plant.

Epigral serves over 15 downstream industries such as construction, pharmaceuticals, agrochemicals, textiles, and water treatment. Its R&D centre in Changodar, Ahmedabad—recognised by the Department of Scientific and Industrial Research (DSIR)—drives innovation in specialty chemicals and intermediates. The workforce stood at 1,079 full-time employees as of March 31, 2025, with an average age of 36 years.

The Company has also been the first in India to produce bio-based ECH, establish a Chlorotoluenes value chain, and emerge as the largest domestic CPVC Resin producer. It holds multiple ISO certifications, REACH registration, and recognitions such as Responsible Care by the Indian Chemical Council.

Epigral Limited Business Segment

• Epigral’s revenue mix reflects a strategic shift from basic chemicals to derivatives and specialty products. In FY 2024-25, Derivatives and Specialty businesses contributed 54% of revenues, compared with 45% in FY 2023-24 and 30% in FY 2022-23
• Geographically, the Company derived 93% of revenues from India and 6.6% from exports in FY 2024-25, up from 4.5% in the previous year.

Epigral Limited Key Management

• Mr. Maulik Patel – Chairman & Managing Director

• Mr. Kaushal Soparkar – Executive Director

Latest Updates on Epigral Limited

• In FY 2024-25, Epigral reported its highest-ever revenue of Rs 2,565 crore and EBITDA of Rs 711 crore, supported by strong performance in specialty chemicals. 
• The Company raised Rs 333 crore through a Qualified Institutional Placement, part of which was used to repay debt, strengthening its balance sheet. Net debt/EBITDA improved from 2.0x to 0.7x, and CRISIL upgraded the rating on long-term facilities to ‘AA/Stable’.
• Key commissioning during the year included a 35,000 TPA CPVC Compound facility, India’s first Chlorotoluenes value chain, and an 18.34 MW wind-solar hybrid power plant. Strategic announcements included doubling CPVC Resin capacity to 1,50,000 TPA (to become the world’s largest plant) and expanding ECH capacity to 1,00,000 TPA (India’s largest) by FY 2026-27. The Company also acquired 100 acres of land adjacent to its Dahej complex for future growth.